Combination of alpha lipoic acid and superoxide dismutase leads to physiological and symptomatic improvements in diabetic neuropathy

被引：43
作者：
Bertolotto F. [1 ]
Massone A. [1 ]
机构：
[1] Laboratorio di Neurofisiologia, Unità Spinale, Ospedale Santa Corona di Pietra Ligure, Savona
来源：
Drugs in R&D | 2012年 / 12卷 / 1期
关键词：
Diabetes-mellitus; Diabetic-neuropathies; Superoxide-dismutase; Thioctic-acid;
D O I：
10.2165/11599200-000000000-00000
中图分类号：
学科分类号：
摘要：
Background and Objective: The management of diabetic neuropathy is still a challenge for physicians. The aim of this study was to assess the efficacy of a new combination of alpha lipoic acid and superoxide dismutase for the treatment of diabetic neuropathy. Methods: The setting of this study was ambulatory (outpatient) care. A prospective, non-randomized, open-label study was conducted in 50 patients with diabetes mellitus and with a deficit in both motor and sensory nerve conduction. Treatment was with a new combination of alpha lipoic acid and superoxide dismutase (ALA600SOD®) for 4 months. Electroneurographic parameters and perceived pain were assessed at baseline and after treatment. Results: After 4 months of treatment, patients significantly (p < 0.001) improved their electroneurographic parameters and their perception of pain. Best improvements were observed in sensory nerve conduction. Conclusion: The combination of two powerful antioxidant agents leads to improvement in both subjective and objective parameters in patients with diabetic neuropathy. New profitable directions for investigations are opened for a non-invasive treatment of diabetic neuropathy in the future. © 2012 Adis Data Information BV. All rights reserved.
引用
收藏
页码：29 / 34
页数：5
相关论文
共 30 条
  • [1] Mijnhout G.S., Alkhalaf A., Kleefstra N., Et al., Alpha lipoic acid a new treatment for neuropathic pain in patients with diabetes, Neth. J. Med., 68, 4, pp. 158-162, (2010)
  • [2] Van Acker K., Bouhassire D., De Bacquer D., Et al., Prevalence and impact on quality of life of peripheral neuropathy with or without neuropatic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics, Diabetes Metab., 35, pp. 206-213, (2009)
  • [3] Boulton A.J.M., Vinik A.I., Arezzo J.C., Bril V., Feldman E.L., Freeman R., Malik R.A., Maser R.E., Sosenko J.M., Ziegler D., Diabetic neuropathies: A statement by the American Diabetes Association, Diabetes Care, 28, 4, pp. 956-962, (2005)
  • [4] Vallianou N., Evangelopoulos A., Koutalas P., Alpha-lipoic acid and diabetic neuropathy, Rev. Diabet Stud., 6, 4, pp. 230-236, (2009)
  • [5] Daousi C., Benbow S.J., Woodward A., MacFarlane I.A., The natural history of chronic painful peripheral neuropathy in a community diabetes population, Diabetic Medicine, 23, 9, pp. 1021-1024, (2006)
  • [6] Davies M., Brophy S., Williams R., Taylor A., The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes, Diabetes Care, 29, 7, pp. 1518-1522, (2006)
  • [7] Greco D., Bambina F., Pisciotta M., Et al., Clinical characteristics and associated comorbidities in diabetic patients with cranial nerve palsies, J. Endocrinol., (2011)
  • [8] Gries F.A., Cameron N.E., Low P.A., Et al., Textbook of diabetic neuropathy, Stuttgart: Thieme, (2003)
  • [9] Ziegler D., Ametov A., Barinov A., Dyck P.J., Gurieva I., Low P.A., Munzel U., Yakhno N., Raz I., Novosadova M., Maus J., Samigullin R., Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy, Diabetes Care, 29, 11, pp. 2365-2370, (2006)
  • [10] Ceriello A., Testa R., Antioxidant anti-inflammatory treatment in type 2 diabetes, Diabetes Care, 2, 32 SUPPL., (2009)
123